Bernadette Eichelberger
Overview
Explore the profile of Bernadette Eichelberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pawloski P, McDermott C, Marshall J, Pindolia V, Lockhart C, Panozzo C, et al.
J Natl Compr Canc Netw
. 2021 Aug;
PMID: 34399406
Background: Chemotherapy-induced febrile neutropenia (FN) is prevented or minimized with granulocyte colony-stimulating factors (G-CSFs). Several G-CSF biosimilars are approved in the United States. The Biologics and Biosimilars Collective Intelligence Consortium...
2.
Zhang J, Sridhar G, Barr C, Eichelberger B, Lockhart C, Marshall J, et al.
J Manag Care Spec Pharm
. 2020 Apr;
26(4):417-490.
PMID: 32223608
Background: There is a need for postmarketing evidence generation for novel biologics and biosimilars. Objective: To assess the feasibility, strengths, and limitations of the Biologics and Biosimilars Collective Intelligence Consortium...
3.
Kent D, McMahill-Walraven C, Panozzo C, Pawloski P, Haynes K, Marshall J, et al.
J Manag Care Spec Pharm
. 2019 Aug;
25(11):1162-1171.
PMID: 31405345
Background: As new biosimilar and follow-on insulins enter the market, more data are needed on safety, effectiveness, and patterns of use for these products to inform prescriber and patient decision-making...
4.
McMahill-Walraven C, Kent D, Panozzo C, Pawloski P, Haynes K, Marshall J, et al.
J Manag Care Spec Pharm
. 2019 Aug;
25(11):1156-1161.
PMID: 31397619
Introduction: As clinical trials test efficacy rather than effectiveness of medications, real-world effectiveness data often vary from clinical trial data. Given the recent market entry of multiple biologics and biosimilars,...
5.
Desai R, Kim S, Curtis J, Bosco J, Eichelberger B, Barr C, et al.
Pharmacoepidemiol Drug Saf
. 2019 Jul;
29(7):757-769.
PMID: 31298463
Purpose: As more biosimilars become available in the United States, postapproval noninterventional studies describing biosimilar switching and comparing effectiveness and/or safety between switchers and nonswitchers will play a key role...
6.
Perfetto E, Anyanwu C, Pickering M, Zaghab R, Graff J, Eichelberger B
J Manag Care Spec Pharm
. 2016 May;
22(6):609-16.
PMID: 27231789
Background: Understanding how treatments work in the real world and in real patients is an important and complex task. In recent years, comparative effectiveness research (CER) studies have become more...
7.
Baldziki M, Brown J, Chan H, Cheetham T, Conn T, Daniel G, et al.
J Manag Care Spec Pharm
. 2015 Jan;
21(1):23-34.
PMID: 25562770
Background: The Biologics Price Competition and Innovation Act, introduced as part of the Affordable Care Act, directed the FDA to create an approval pathway for biologic products shown to be...